Methadone in Post-Herpetic Neuralgia Pain (NPH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01752699
Recruitment Status : Completed
First Posted : December 19, 2012
Last Update Posted : March 18, 2013
Information provided by (Responsible Party):
Daniel Ciampi Araujo de Andrade, University of Sao Paulo

Brief Summary:
Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

Condition or disease Intervention/treatment Phase
Post-herpetic Neuralgia Drug: Methadone Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Methadone in Post-Herpetic Neuralgia Pain
Study Start Date : January 1998
Actual Primary Completion Date : February 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shingles

Arm Intervention/treatment
Experimental: Methadone
in this arm patients will take methadone 5mg.
Drug: Methadone
patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.

Experimental: Placebo
in this arm patients will take placebo pills.
Drug: Placebo
patients with post-herpetic neuralgia take placebo to treat the pain symptoms.

Primary Outcome Measures :
  1. Change in baseline Pain [ Time Frame: baseline (visit inclusion) and three moths latter ]
    Assessing by verbal analog scale (VAS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with chronic (>6 months) symptomatic PHN
  • with visual analogical scale >40/100mm
  • use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)

Exclusion Criteria:

  • Don't full the criteria above

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Daniel Ciampi Araujo de Andrade, MD, PhD, University of Sao Paulo Identifier: NCT01752699     History of Changes
Other Study ID Numbers: NPH
First Posted: December 19, 2012    Key Record Dates
Last Update Posted: March 18, 2013
Last Verified: March 2013

Keywords provided by Daniel Ciampi Araujo de Andrade, University of Sao Paulo:
neuropathic pain,
post-herpetic neuralgia,

Additional relevant MeSH terms:
Neuralgia, Postherpetic
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents